Detailed description page of THPdb

Details of Th1092 which contains 3 entries.

Entry 1
(1) Primary information
ID 1470
ThPP ID Th1092
Therapeutic Peptide/Protein Name Arcitumomab
Sequence Anti-CEA heavy chain 1EVKLVESGGGLVQPGGSLRLSCATSGFT view full sequnce in fasta
Functional Classification IIb
Molecular Weight 144482.5
Chemical Formula C6398H9900N1714O1995S54
Isoelectric Point 8.26
Hydrophobicity -0.423
Melting Point (℃) 61 (FAB fr
Half Life Approximately 1 hour
Description Reduced Fab fragment of the murine IgG1 monoclonal antibody IMMU-4 (also called NP-4) with specificity for carcinoembryonic antigen. Covalently labeled with Technitium 99.
Indication/Disease For imaging colorectal tumors
Pharmacodynamics Binds to the carcinoembryonic antigen, which is a cell surface protein generally overexpressed in colon (and other) cancers. The radioactive Tc99, which is covalently attached to the antibody, allows radiodiagnostic detection of CEA expressing cells and tumors
Mechanism of Action Binds selectively to cell-surface carcinoembryonic antigen (CEA) expressed on colorectal tumors.
Toxicity N.A.
Metabolism Most likely removed by opsonization via the reticuloendothelial system, or by human antimurine antibody production
Absorption N.A.
Volume of Distribution N.A.
Clearance N.A.
Categories Diagnostic Agents
Patents Number US8420081
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target Vascular endothelial growth factor A,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immunoglobulin gamma Fc region receptor III-A,High affinity immunoglobulin gamma Fc receptor I,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c
Information of corresponding available drug in the market
Brand Name CEA-Scan
Company N.A.
Brand Discription Arcitumomab, a Fab fragment of the murine monoclonal antibody IMMU-4 of the IgG1 subclass, is directed against a 200,000-dalton carcinoembryonic antigen (CEA) that is expressed on the cell surface of numerous tumors, particularly of the gastrointestinal tract (including fetal gastrointestinal tissues) and in certain inflammatory states (e.g., Crohns disease). The Fab fragment is used rather than the whole monoclonal antibody because of its more favorable pharmacokinetics (faster blood clearance and minimal liver metabolism) also, it minimizes the frequency of human anti-mouse antibody response. Less than 50% antigen complexation with technetium Tc 99m arcitumomab occurs with plasma CEA levels of up to 2000 nanograms per mL, and antigen complexation is not detectable at serum CEA levels below 250 nanograms per mL. The distribution of radioactivity is recorded by planar scintigraphy and single photon emission computed tomography (SPECT)
Prescribed for Diagnostic: Carcinoma, colorectal (diagnosis adjunct)â€”Technetium Tc 99m arcitumomab, in conjunction with standard diagnostic modalities (e.g., computed tomography [CT]), is indicated to detect, locate, and determine the extent of recurrent and/or metastatic colorectal carcinoma involving the liver and the extrahepatic abdominal and pelvic regions in patients with a histologically confirmed diagnosis of colorectal carcinoma. maging with technetium Tc 99m arcitumomab provides additional information in patients suspected of tumor recurrence or metastasis who have elevated or rising serum carcinoembryonic antigen (CEA) but no evidence of disease by standard diagnostic methods (e.g., abdominal and pelvic CT, chest radiograph, colonoscopy, barium enema).
Chemical Name N. A.
Formulation N. A.
Physcial Appearance N. A.
Route of Administration N. A.
Recommended Dosage N. A.
Contraindication You should not receive this medicine if you have had an allergic reaction to arcitumomab, or to products made from mice. Technetium Tc 99m arcitumomab may have a role as an adjunct to mammography in the diagnosis of primary, recurrent, or metastatic mammary cancer, particularly in patients without palpable abnormalities who have indeterminate mammograms.
Side Effects Allergic reaction: Itching or hives, swelling in your face or hands, swelling or tingling in your mouth or throat, chest tightness, trouble breathing, Chest tightness or severe cough, Headache, Joint pain, Mild skin rash or itching, Nausea or upset stomach.
Useful Link http://umm.edu/health/medical/drug-notes/notes/arcitumomab-injection http://www.drugs.com/mmx/cea-scan.html
PubMed ID 20641871, 11776491, 10855627, 10656657
3-D Structure Th1092 (View) or (Download)

Entry 2
(2) Primary information
ID 1471
ThPP ID Th1092
Therapeutic Peptide/Protein Name Arcitumomab
Sequence Anti-CEA heavy chain 1EVKLVESGGGLVQPGGSLRLSCATSGFT view full sequnce in fasta
Functional Classification IIb
Molecular Weight 144482.5
Chemical Formula C6398H9900N1714O1995S55
Isoelectric Point 8.26
Hydrophobicity -0.423
Melting Point (℃) 62 (FAB fr
Half Life Approximately 1 hour
Description Reduced Fab fragment of the murine IgG1 monoclonal antibody IMMU-4 (also called NP-4) with specificity for carcinoembryonic antigen. Covalently labeled with Technitium 99.
Indication/Disease For imaging colorectal tumors
Pharmacodynamics Binds to the carcinoembryonic antigen, which is a cell surface protein generally overexpressed in colon (and other) cancers. The radioactive Tc99, which is covalently attached to the antibody, allows radiodiagnostic detection of CEA expressing cells and tumors
Mechanism of Action Binds selectively to cell-surface carcinoembryonic antigen (CEA) expressed on colorectal tumors.
Toxicity N.A.
Metabolism Most likely removed by opsonization via the reticuloendothelial system, or by human antimurine antibody production
Absorption N.A.
Volume of Distribution N.A.
Clearance N.A.
Categories Diagnostic Agents
Patents Number US7790142
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target N.A.
Information of corresponding available drug in the market
Brand Name N.A.
Company N.A.
Brand Discription N.A.
Prescribed for N.A.
Chemical Name N. A.
Formulation N. A.
Physcial Appearance N. A.
Route of Administration N. A.
Recommended Dosage N. A.
Contraindication N. A.
Side Effects N. A.
Useful Link N. A.
PubMed ID 20641871, 11776491, 10855627, 10656657
3-D Structure Th1092 (View) or (Download)

Entry 3
(3) Primary information
ID 1472
ThPP ID Th1092
Therapeutic Peptide/Protein Name Arcitumomab
Sequence Anti-CEA heavy chain 1EVKLVESGGGLVQPGGSLRLSCATSGFT view full sequnce in fasta
Functional Classification IIb
Molecular Weight 144482.5
Chemical Formula C6398H9900N1714O1995S56
Isoelectric Point 8.26
Hydrophobicity -0.423
Melting Point (℃) 63 (FAB fr
Half Life Approximately 1 hour
Description Reduced Fab fragment of the murine IgG1 monoclonal antibody IMMU-4 (also called NP-4) with specificity for carcinoembryonic antigen. Covalently labeled with Technitium 99.
Indication/Disease For imaging colorectal tumors
Pharmacodynamics Binds to the carcinoembryonic antigen, which is a cell surface protein generally overexpressed in colon (and other) cancers. The radioactive Tc99, which is covalently attached to the antibody, allows radiodiagnostic detection of CEA expressing cells and tumors
Mechanism of Action Binds selectively to cell-surface carcinoembryonic antigen (CEA) expressed on colorectal tumors.
Toxicity N.A.
Metabolism Most likely removed by opsonization via the reticuloendothelial system, or by human antimurine antibody production
Absorption N.A.
Volume of Distribution N.A.
Clearance N.A.
Categories Diagnostic Agents
Patents Number US8226949
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target Carcinoembryonic antigen-related cell adhesion molecule 1
Information of corresponding available drug in the market
Brand Name N.A.
Company N.A.
Brand Discription N.A.
Prescribed for N.A.
Chemical Name N. A.
Formulation N. A.
Physcial Appearance N. A.
Route of Administration N. A.
Recommended Dosage N. A.
Contraindication N. A.
Side Effects N. A.
Useful Link N. A.
PubMed ID 20641871, 11776491, 10855627, 10656657
3-D Structure Th1092 (View) or (Download)

OSDDlinux

Raghava's Group

IMTECH

CSIR

CRDD
CPPSITE 2.0

(1) Primary information
Entry 1
ID	1470
ThPP ID	Th1092
Therapeutic Peptide/Protein Name	Arcitumomab
Sequence	Anti-CEA heavy chain 1EVKLVESGGGLVQPGGSLRLSCATSGFT view full sequnce in fasta
Functional Classification	IIb
Molecular Weight	144482.5
Chemical Formula	C6398H9900N1714O1995S54
Isoelectric Point	8.26
Hydrophobicity	-0.423
Melting Point (℃)	61 (FAB fr
Half Life	Approximately 1 hour
Description	Reduced Fab fragment of the murine IgG1 monoclonal antibody IMMU-4 (also called NP-4) with specificity for carcinoembryonic antigen. Covalently labeled with Technitium 99.
Indication/Disease	For imaging colorectal tumors
Pharmacodynamics	Binds to the carcinoembryonic antigen, which is a cell surface protein generally overexpressed in colon (and other) cancers. The radioactive Tc99, which is covalently attached to the antibody, allows radiodiagnostic detection of CEA expressing cells and tumors
Mechanism of Action	Binds selectively to cell-surface carcinoembryonic antigen (CEA) expressed on colorectal tumors.
Toxicity	N.A.
Metabolism	Most likely removed by opsonization via the reticuloendothelial system, or by human antimurine antibody production
Absorption	N.A.
Volume of Distribution	N.A.
Clearance	N.A.
Categories	Diagnostic Agents
Patents Number	US8420081
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	Vascular endothelial growth factor A,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immunoglobulin gamma Fc region receptor III-A,High affinity immunoglobulin gamma Fc receptor I,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c
Information of corresponding available drug in the market
Brand Name	CEA-Scan
Company	N.A.
Brand Discription	Arcitumomab, a Fab fragment of the murine monoclonal antibody IMMU-4 of the IgG1 subclass, is directed against a 200,000-dalton carcinoembryonic antigen (CEA) that is expressed on the cell surface of numerous tumors, particularly of the gastrointestinal tract (including fetal gastrointestinal tissues) and in certain inflammatory states (e.g., Crohns disease). The Fab fragment is used rather than the whole monoclonal antibody because of its more favorable pharmacokinetics (faster blood clearance and minimal liver metabolism) also, it minimizes the frequency of human anti-mouse antibody response. Less than 50% antigen complexation with technetium Tc 99m arcitumomab occurs with plasma CEA levels of up to 2000 nanograms per mL, and antigen complexation is not detectable at serum CEA levels below 250 nanograms per mL. The distribution of radioactivity is recorded by planar scintigraphy and single photon emission computed tomography (SPECT)
Prescribed for	Diagnostic: Carcinoma, colorectal (diagnosis adjunct)â€”Technetium Tc 99m arcitumomab, in conjunction with standard diagnostic modalities (e.g., computed tomography [CT]), is indicated to detect, locate, and determine the extent of recurrent and/or metastatic colorectal carcinoma involving the liver and the extrahepatic abdominal and pelvic regions in patients with a histologically confirmed diagnosis of colorectal carcinoma. maging with technetium Tc 99m arcitumomab provides additional information in patients suspected of tumor recurrence or metastasis who have elevated or rising serum carcinoembryonic antigen (CEA) but no evidence of disease by standard diagnostic methods (e.g., abdominal and pelvic CT, chest radiograph, colonoscopy, barium enema).
Chemical Name	N. A.
Formulation	N. A.
Physcial Appearance	N. A.
Route of Administration	N. A.
Recommended Dosage	N. A.
Contraindication	You should not receive this medicine if you have had an allergic reaction to arcitumomab, or to products made from mice. Technetium Tc 99m arcitumomab may have a role as an adjunct to mammography in the diagnosis of primary, recurrent, or metastatic mammary cancer, particularly in patients without palpable abnormalities who have indeterminate mammograms.
Side Effects	Allergic reaction: Itching or hives, swelling in your face or hands, swelling or tingling in your mouth or throat, chest tightness, trouble breathing, Chest tightness or severe cough, Headache, Joint pain, Mild skin rash or itching, Nausea or upset stomach.
Useful Link	http://umm.edu/health/medical/drug-notes/notes/arcitumomab-injection http://www.drugs.com/mmx/cea-scan.html
PubMed ID	20641871, 11776491, 10855627, 10656657
3-D Structure	Th1092 (View) or (Download)

(2) Primary information
Entry 2
ID	1471
ThPP ID	Th1092
Therapeutic Peptide/Protein Name	Arcitumomab
Sequence	Anti-CEA heavy chain 1EVKLVESGGGLVQPGGSLRLSCATSGFT view full sequnce in fasta
Functional Classification	IIb
Molecular Weight	144482.5
Chemical Formula	C6398H9900N1714O1995S55
Isoelectric Point	8.26
Hydrophobicity	-0.423
Melting Point (℃)	62 (FAB fr
Half Life	Approximately 1 hour
Description	Reduced Fab fragment of the murine IgG1 monoclonal antibody IMMU-4 (also called NP-4) with specificity for carcinoembryonic antigen. Covalently labeled with Technitium 99.
Indication/Disease	For imaging colorectal tumors
Pharmacodynamics	Binds to the carcinoembryonic antigen, which is a cell surface protein generally overexpressed in colon (and other) cancers. The radioactive Tc99, which is covalently attached to the antibody, allows radiodiagnostic detection of CEA expressing cells and tumors
Mechanism of Action	Binds selectively to cell-surface carcinoembryonic antigen (CEA) expressed on colorectal tumors.
Toxicity	N.A.
Metabolism	Most likely removed by opsonization via the reticuloendothelial system, or by human antimurine antibody production
Absorption	N.A.
Volume of Distribution	N.A.
Clearance	N.A.
Categories	Diagnostic Agents
Patents Number	US7790142
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	N.A.
Information of corresponding available drug in the market
Brand Name	N.A.
Company	N.A.
Brand Discription	N.A.
Prescribed for	N.A.
Chemical Name	N. A.
Formulation	N. A.
Physcial Appearance	N. A.
Route of Administration	N. A.
Recommended Dosage	N. A.
Contraindication	N. A.
Side Effects	N. A.
Useful Link	N. A.
PubMed ID	20641871, 11776491, 10855627, 10656657
3-D Structure	Th1092 (View) or (Download)

(3) Primary information
Entry 3
ID	1472
ThPP ID	Th1092
Therapeutic Peptide/Protein Name	Arcitumomab
Sequence	Anti-CEA heavy chain 1EVKLVESGGGLVQPGGSLRLSCATSGFT view full sequnce in fasta
Functional Classification	IIb
Molecular Weight	144482.5
Chemical Formula	C6398H9900N1714O1995S56
Isoelectric Point	8.26
Hydrophobicity	-0.423
Melting Point (℃)	63 (FAB fr
Half Life	Approximately 1 hour
Description	Reduced Fab fragment of the murine IgG1 monoclonal antibody IMMU-4 (also called NP-4) with specificity for carcinoembryonic antigen. Covalently labeled with Technitium 99.
Indication/Disease	For imaging colorectal tumors
Pharmacodynamics	Binds to the carcinoembryonic antigen, which is a cell surface protein generally overexpressed in colon (and other) cancers. The radioactive Tc99, which is covalently attached to the antibody, allows radiodiagnostic detection of CEA expressing cells and tumors
Mechanism of Action	Binds selectively to cell-surface carcinoembryonic antigen (CEA) expressed on colorectal tumors.
Toxicity	N.A.
Metabolism	Most likely removed by opsonization via the reticuloendothelial system, or by human antimurine antibody production
Absorption	N.A.
Volume of Distribution	N.A.
Clearance	N.A.
Categories	Diagnostic Agents
Patents Number	US8226949
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	Carcinoembryonic antigen-related cell adhesion molecule 1
Information of corresponding available drug in the market
Brand Name	N.A.
Company	N.A.
Brand Discription	N.A.
Prescribed for	N.A.
Chemical Name	N. A.
Formulation	N. A.
Physcial Appearance	N. A.
Route of Administration	N. A.
Recommended Dosage	N. A.
Contraindication	N. A.
Side Effects	N. A.
Useful Link	N. A.
PubMed ID	20641871, 11776491, 10855627, 10656657
3-D Structure	Th1092 (View) or (Download)